BACE1 and HIV-associated neurocognitive disorder: If this mouse model translates to the clinical syndrome, then a pharmacotherapeutic strategy aimed at opposing the EFV-mediated reduced microglial Aβ clearance and/or EFV-mediated neuronal Aβ over production via BACE-1 should be beneficial to prevent or treat HAND.